ESSA Pharma Inc. (EPIX)
$3.02
+0.05 (+1.68%)
Rating:
Recommendation:
Buy
| Symbol | EPIX |
|---|---|
| Price | $3.02 |
| Beta | 2.106 |
| Volume Avg. | 0.23M |
| Market Cap | 133.159M |
| Shares () | - |
| 52 Week Range | 1.4-8.03 |
| 1y Target Est | - |
| DCF Unlevered | EPIX DCF -> | |
|---|---|---|
| DCF Levered | EPIX LDCF -> | |
| ROE | -19.28% | Sell |
| ROA | -19.85% | Sell |
| Operating Margin | - | |
| Debt / Equity | 1.84% | Neutral |
| P/E | -3.87 | Strong Sell |
| P/B | 0.82 | Buy |
Latest EPIX news
About
Download (Excel)Dr. David Ross Parkinson M.D.
Healthcare
Biotechnology
NASDAQ Capital Market
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.